Bimekizumab
UCB Biopharma
['hidradenitis', 'ucb_news']
for media: new late breaking phase 3 data in #hidradenitissuppurativa presented at #aad 2023. click here to learn more: 
A global biopharma company focusing on creating value for people living with neurology and immunology diseases. 
We are inspired by patients, driven by science.